CA209204 A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
March 18, 2015
End Date
September 17, 2021
Awarded By
Bristol-Myers Squibb Company
Start Date
March 18, 2015
End Date
September 17, 2021